Research analysts covering Genfit.
Recent press releases and 8-K filings for GNFT.
GENFIT Announces Voluntary Delisting of ADSs from Nasdaq
GNFT
Delisting/Listing Issues
- GENFIT announced its intention to voluntarily delist its American Depositary Shares (ADSs) from The Nasdaq Global Select Market.
- The delisting is anticipated to be effective prior to the opening of trading on November 20, 2025.
- The company will remain listed on the regulated market of Euronext Paris as its primary trading market.
- This decision reflects a strategic intent to simplify corporate structure, improve operational efficiency, and streamline operations.
- ADS holders have until about February 6, 2026, to surrender ADSs for delivery of the underlying ordinary shares, after which the Depositary may elect to sell the underlying ordinary shares.
Oct 30, 2025, 8:00 PM
Genfit Announces Advances in ACLF Pipeline and Iqirvo Data at AASLD 2025
GNFT
New Projects/Investments
- GENFIT will present new data on its Acute on-Chronic Liver Failure (ACLF) pipeline programs, including G1090N, SRT-015, and CLM-022, at The Liver Meeting® 2025.
- Clinical safety data and markers of early efficacy for G1090N, GENFIT's lead ACLF program, are anticipated by the end of 2025.
- Partner Ipsen will present new Iqirvo® (elafibranor) data for Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC), highlighting its potential in rare cholestatic liver diseases.
- Iqirvo® (elafibranor) received accelerated approval in 2024 for PBC and is currently marketed in several countries.
Oct 28, 2025, 9:10 PM
Genfit S.A. Reports Q2 2025 Results, Secures Financing, and Discontinues VS-01 Program
GNFT
Debt Issuance
Guidance Update
Earnings
- GENFIT secured a royalty financing agreement with HCRx for up to €185 million, with €130 million upfront, which significantly extends its cash runway beyond the end of 2028. Concurrently, the company repurchased 99% of its outstanding OCEANEs for €61.7 million.
- The company received a €26.5 million milestone payment in July 2025 for Iqirvo® (elafibranor) and reported accelerated sales growth of €59 million for the drug in the first half of 2025.
- GENFIT decided to discontinue its VS-01 program in ACLF on September 19, 2025, following a Serious Adverse Event, which will result in a full impairment of the €45.8 million intangible asset in the second half of 2025 and is expected to substantially reduce operating expenses.
- For the first half of 2025, GENFIT reported a net loss of €9,956 thousand on revenue of €33,488 thousand, compared to a net profit of €30,311 thousand and revenue of €58,973 thousand in the first half of 2024. Cash and cash equivalents increased to €107,511 thousand as of June 30, 2025.
Sep 22, 2025, 8:20 PM
Genfit Reports First-Half 2025 Financial Results and Corporate Updates
GNFT
Earnings
Guidance Update
New Projects/Investments
- GENFIT reported a net loss of €10.0 million for the first half of 2025, compared to a net profit of €30.3 million in the same period of 2024, with revenues and other income totaling €35.7 million.
- As of June 30, 2025, cash and cash equivalents were €107.5 million, excluding a €26.5 million milestone payment received in July 2025, and the company's cash runway is now projected to extend beyond 2028.
- The VS-01 program in ACLF was discontinued due to a Serious Adverse Event, with development now reprioritized for Urea Cycle Disorder (UCD).
- Ipsen's Iqirvo® (elafibranor) for PBC generated €6.9 million in royalty revenue for GENFIT in the first half of 2025, and a key competitor, OCALIVA®, exited the US market in September 2025, which is expected to support Iqirvo® sales.
Sep 22, 2025, 8:10 PM
Genfit Discontinues VS-01 Program in ACLF, Refocuses on UCD
GNFT
New Projects/Investments
Guidance Update
- Genfit S.A. has decided to discontinue its VS-01 program in Acute-on-Chronic Liver Failure (ACLF) following a Serious Adverse Event (peritonitis case) reported in the UNVEIL-IT® clinical trial and feedback from the independent Data Monitoring Committee.
- The development of VS-01 will be refocused on Urea Cycle Disorder (UCD), with preclinical evaluation continuing in this indication.
- This discontinuation is expected to result in a substantial reduction in operating expenses, providing strategic flexibility.
- The company anticipates this will extend its projected cash runway by at least a year versus previous guidance, i.e., beyond 2028.
- Genfit remains committed to ACLF and plans to accelerate the development of four other assets (G1090N, SRT-015, CLM-022, and VS-02-HE) in its pipeline for ACLF.
Sep 19, 2025, 8:10 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more